Table 2.
KarXT treatment effect on cognitive performance by baseline impairment subgroup.
| Sample | LS means change from baseline at day 35 | 95% confidence interval | ||||
|---|---|---|---|---|---|---|
| Treatment | Estimate (SE) | Lower | Upper | p value | Cohen’s d | |
| Minimally impaired | KarXT (n = 37) | –0.18 (0.13) | –0.44 | 0.09 | 0.19 | 0.22 |
| Placebo (n = 28) | –0.22 (0.15) | –0.52 | 0.08 | 0.15 | 0.28 | |
| KarXT vs. placebo | 0.04 (0.16) | –0.28 | 0.37 | 0.79 | 0.05 | |
| Impaired | KarXT (n = 23) | 0.57 (0.19) | 0.18 | 0.95 | 0.01 | 0.61 |
| Placebo (n = 37) | 0.07 (0.13) | –0.19 | 0.33 | 0.59 | 0.09 | |
| KarXT vs. placebo | 0.50 (0.22) | 0.04 | 0.95 | 0.03 | 0.50 | |
LS means and p values are derived from post hoc ANCOVA models described earlier, with covariates of site, gender, age, and baseline performance. ANCOVA analysis of covariance, LS least squares.